Uncategorized

European Medicines Agency (EMA) Grants Orphan Drug Designation (ODD) to GC Biopharma’s Treatment for Sanfilippo Syndrome (Type A)

GC Biopharma Corp. announced that the European Medicines Agency has granted Orphan Drug Designation to its intracerebroventricular Enzyme Replacement Therapy candidate, GC1130A, designed for Sanfilippo Syndrome type A, developed in collaboration with Novel Pharma.

European Medicines Agency (EMA) Grants Orphan Drug Designation (ODD) to GC Biopharma’s Treatment for Sanfilippo Syndrome (Type A) Read More »

Gannex’s Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH

Gannex Pharma Company Ltd, a wholly-owned company of Ascletis Pharma Inc., announced that its strategic partner, Sagimet Biosciences Inc., reported positive topline results from Sagimet’s FASCINATE-2 Phase 2b clinical trial of denifanstat versus placebo in biopsy-confirmed non-alcoholic steatohepatitis patients with stage 2 or stage 3 fibrosis at week 52.

Gannex’s Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH Read More »

Scroll to Top